1
Participants
Start Date
March 31, 2013
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
Everolimus
"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
Hospital São João de Deus/Fundação Geraldo Corrêa, Divinópolis
Hospital Márcio Cunha/Fundação São Francisco Xavier, Ipatinga
Fundação IMEPEN, Juiz de Fora
Hospital do Rim de MOntes Claros/Irmandade Nossa Senhora das Mercês, Montes Claros
Collaborators (1)
Novartis
INDUSTRY
Helady Pinheiro, MD, PhD
OTHER